# The Serologically Silent Storm: Diagnostic Challenges in Renal-First Lupus Nephritis Presenting with Microscopic Hematuria and Proteinuria *A Clinical Case Report and Educational Review* **Medical Associates Department of Nephrology \| University of Illinois College of Medicine at Peoria \| University of Dubuque Physician Assistant Program \| UDPA Butler School of Medicine** **Andrew Bland, MD, FACP, FAAP** ------------------------------------------------------------------------ ## Executive Summary - Kidney disease can precede a recognized systemic lupus diagnosis. Negative anti-dsDNA or normal complement does not exclude active nephritis; a negative ANA warrants careful assay and differential-diagnosis review. - Full-house staining supports lupus nephritis in the appropriate setting but also occurs in nonlupus kidney disease. The 2019 EULAR/ACR classification system requires a qualifying positive ANA at least once before weighted criteria are counted (13,14,31). - Persistent hematuria, proteinuria, or declining kidney function deserves timely evaluation. Biopsy findings may be more severe than the routine clinical picture suggests (5,7,8). - The reported patient progressed to dialysis dependence and continues to make urine. Her activity index of 9/24 and chronicity index of 8/12 inform risk but cannot generate a validated individual probability or timetable of recovery (32). - Exploratory subgroup results do not establish that belimumab is ineffective above a UPCR threshold or that obinutuzumab is superior to another active drug (9,10,20). - Severe kidney impairment raises CNI toxicity concerns. Voclosporin trial eligibility and labeling should not be recast as an absolute contraindication to every CNI. ## 1. Case Presentation A 35-year-old white female with no known history of autoimmune disease presented in late spring/early summer 2024 with severe uncontrolled hypertension. She was referred to Nephrology for evaluation and management of blood pressure, which was eventually controlled on a 3-drug antihypertensive regimen with persistent white coat hypertension phenomenon. During the initial workup, she had microscopic hematuria, which was confounded by significant dysmenorrhea with chronic menstrual spotting. A comprehensive glomerulonephritis panel was negative. ### The Clinical Timeline **Late Spring/Early Summer 2024 — Initial Presentation:** - Severe uncontrolled hypertension with white coat phenomenon - Eventually controlled on 3-drug regimen including olmesartan 40 mg - Microscopic hematuria — confounded by significant dysmenorrhea with chronic spotting - Creatinine: 1.0 mg/dL - Baseline albumin/creatinine ratio: ~200 mg/g - ANA: Negative - Anti-dsDNA: Negative (specific value not documented at this visit) - ANCA: Negative - C3/C4: Normal - Clinical attribution: Microscopic hematuria attributed to menstrual contamination **August 2024 — The Missed Window:** - Albumin/creatinine ratio: 900 mg/g (4.5-fold increase from baseline) - Olmesartan maximized to 40 mg - Blood pressure: Controlled - Creatinine: Stable at 1.0 mg/dL - Subsequent ACR: Improved with ARB maximization - Clinical interpretation: Improvement attributed to successful RAAS blockade > ⚠️ **The Diagnostic Trap:** The August urine albumin/creatinine ratio of 900 mg/g was a substantial abnormality requiring confirmation and evaluation in the context of hematuria. ACR cannot be converted to UPCR by a fixed multiplier. Improvement during ARB therapy does not establish the cause of the kidney disease or exclude ongoing inflammation. **November 2024 — First Signal of Progression:** - Creatinine rose to 1.5 mg/dL - Clinical concern for underlying pathology reinitiated **December 2024 — Diagnostic Workup:** - Creatinine: 2.5 mg/dL (150% increase from baseline over ~6 months) - Repeat glomerulonephritis serologic panel: - Anti-dsDNA: 4 IU/mL (negative; reference \<10) - SLE screen: Positive (laboratory does not reflex to titer) - C3: Normal - C4: Normal - Kidney biopsy performed based on unexplained rapid decline in kidney function ### Kidney Biopsy Results | Parameter | Finding | Clinical Significance | |----|----|----| | ISN/RPS Classification | Class IV-G (A) | Diffuse global proliferative lupus nephritis, active | | Activity Index | 9/24 | Moderate-to-high active inflammation | | Chronicity Index | 8/12 | High; significant irreversible damage already present | | UPCR | 9.4 g/g | Severely nephrotic-range proteinuria | | Immunofluorescence | “Full house” pattern | IgG, IgA, IgM, C3, C1q deposition — supports lupus nephritis in context, but is not specific to lupus (31) | | Crescents | **Fibrocellular and fibrotic crescents present** | Indicates prolonged aggressive disease with active and chronic components | > **Note on Crescents:** Fibrocellular crescents contain both cellular and fibrous components, whereas fibrous crescents predominantly reflect chronic scarring. The combination supports mixed active and chronic injury. It does not establish precisely when injury began or what the biopsy would have shown earlier. ### Clinical Update: Progression to Dialysis Dependence Despite initiation of aggressive immunosuppressive therapy, the patient’s kidney function continued to decline. The acute glomerulonephritis progressed to rapidly progressive glomerulonephritis (RPGN), and she became hemodialysis-dependent. **Current Status:** - Hemodialysis-dependent - **Continues to produce urine** (non-oliguric) - Receiving ongoing immunosuppression per treatment plan Continued urine output is useful to track but does not by itself establish adequate solute clearance or predict dialysis independence (see Section 7). ### The Diagnostic Paradox The biopsy revealed severe, active Class IV lupus nephritis with high activity index (9/24) indicating urgent need for aggressive immunosuppression, yet the patient had: - **No prior SLE diagnosis** - **No extrarenal manifestations of lupus** - **Negative anti-dsDNA antibodies** (4 IU/mL) - **Normal complement levels** (C3 and C4) - **Negative ANA** at initial presentation (with positive SLE screen on repeat testing) This constellation represents the diagnostic challenge of **serologically quiet, renal-first lupus nephritis** — a presentation requiring integration of pathology, longitudinal clinical findings, serology, and alternative diagnoses. ------------------------------------------------------------------------ ## 2. The Diagnostic Red Herrings ### Red Herring \#1: The “Non-Clean-Catch” Dismissal Menstrual contamination is a plausible explanation for an isolated urine result. Confirm it with a properly collected specimen after bleeding resolves when clinically appropriate. Persistent hematuria, especially with proteinuria or declining kidney function, requires further evaluation. Repeat urinalysis with microscopy, quantify protein, assess kidney function and blood pressure, and consider nephrology review. Selected glomerulonephritis tests and biopsy depend on the complete presentation. A catheterized specimen is an option when necessary, not a routine requirement. In this case, the initial attribution to contamination was followed by rising albuminuria and later creatinine. Earlier reassessment offered an opportunity to clarify the diagnosis; the amount of scarring preventable at that point cannot be reconstructed. ### Red Herring \#2: The Negative ANA ANA testing is highly sensitive for SLE, but performance varies with the method, threshold, and clinical population. A negative result lowers the probability of SLE; it does not replace evaluation of unexplained glomerular disease (13). Review the assay, the timing of testing, and any later positive result with rheumatology. In this case the later “positive SLE screen” lacks a documented titer and method, so whether it fulfills the ANA entry requirement cannot be determined from the record. Kidney biopsy defines the injury pattern. Full-house immunofluorescence is characteristic of lupus nephritis but can occur in infection-associated and other nonlupus disease. It is not a standalone diagnostic test for SLE (31). ### Red Herring \#3: The Negative Anti-dsDNA and Normal Complements The repeat glomerulonephritis panel in December showed anti-dsDNA of 4 IU/mL (negative) and normal C3/C4. These findings might suggest that lupus nephritis is unlikely — but this reasoning is fundamentally flawed. #### Anti-dsDNA in Lupus Nephritis vs. Systemic SLE: Critical Distinction Anti-dsDNA and complement are useful components of assessment, but their relationship to renal activity is imperfect. Assay differences and heterogeneous disease biology help explain discordance. The cited small cohort and case report demonstrate possible negative anti-dsDNA results in biopsy-proven nephritis; they do not establish a universal prevalence or prove that isolated nephritis has lower sensitivity than systemic SLE (25,26). The reported anti-dsDNA of 4 IU/mL and normal C3/C4 coexist here with the described active kidney pathology. These blood tests must therefore be interpreted alongside the urine findings, kidney function, and biopsy. Research identifies immune-cell populations within lupus kidneys (4). Local immune mechanisms remain an explanation to investigate, not proof that this patient has a particular tissue B-cell phenotype or requires a specific biologic. Full-house staining does not identify the antigen specificity of the deposited antibodies. There is no validated IgG/IgM anti-dsDNA ratio threshold supplied by the cited evidence that should direct this patient's diagnosis or therapy. ### Red Herring \#4: The Absence of Extrarenal Manifestations Kidney disease can precede recognition of extrarenal lupus. Continue longitudinal clinical and serological review rather than assigning an unsupported frequency or predicting when systemic manifestations will emerge. **Classification is distinct from diagnosis:** the 2019 EULAR/ACR criteria require ANA positivity at least once, at a titer of at least 1:80 on HEp-2 cells or an equivalent test. Class III/IV lupus nephritis contributes 10 points only after that entry criterion is satisfied and when no more likely explanation exists. Biopsy alone does not bypass the ANA requirement (13,14). A patient who does not meet research classification criteria may still need clinical evaluation and treatment. Conversely, full-house staining with absent systemic evidence should prompt a differential that includes nonlupus full-house nephropathy (31). ## 3. The Diagnostic Delay Problem ### Six Months: The Cost of Cognitive Shortcuts The reported sequence was creatinine 1.0 mg/dL in late spring/summer 2024, 1.5 in November, and 2.5 in December, when biopsy was obtained. The urine abnormalities preceded the documented decline in filtration. Observational studies associate diagnostic delay and chronic lesions with worse outcomes (11,15,16). They support timely evaluation; they cannot establish how much of this patient's chronicity index resulted from a particular delay or calculate the benefit of a hypothetical earlier biopsy. A chronicity index of 8/12 denotes substantial chronic injury. It is not a direct measurement of the percentage of nephrons lost, and it cannot be translated into a fixed recovery percentage. ### Clinical Findings Do Not Predict Histologic Severity Routine clinical findings do not reliably measure the full extent of renal inflammation or scarring. The AMP study enrolled patients with SLE already undergoing clinically indicated biopsies; substantial proliferative or membranous disease was found even among those with UPCR below 1 g/g, sometimes with inactive sediment or unremarkable serology (5). This is evidence from a selected biopsy cohort. It does not mean that 92% of all patients with low proteinuria have severe lupus nephritis, nor that any hematuria automatically requires biopsy. The lesson is to integrate persistence, sediment, protein trajectory, kidney function, and the clinical differential. ### 2024 ACR Guideline: Lowered Biopsy Threshold The 2024 ACR guideline conditionally recommends kidney biopsy in people with SLE and proteinuria above 0.5 g/g and/or otherwise unexplained impaired kidney function (8). Biopsy decisions also account for bleeding risk, alternative diagnoses, and whether the result will change management. These recommendations concern suspected nephritis in SLE. A patient without an established SLE diagnosis still warrants timely general nephrology evaluation for unexplained proteinuria, hematuria, or declining kidney function. ### KDIGO 2024: Proteinuria vs Albuminuria — A Critical Distinction Urine albumin/creatinine ratio measures albumin; urine protein/creatinine ratio measures total protein. Their relationship varies by disease and sample, so **do not convert ACR to UPCR using a fixed multiplier**. The patient's August ACR of 900 mg/g was clearly abnormal, regardless of the unavailable simultaneous UPCR. Quantify total protein when needed for a protein-based decision, confirm collection quality, and assess the full trajectory. KDIGO 2024 suggests considering biopsy when proteinuria reaches 500 mg/day in the appropriate SLE evaluation, while emphasizing that clinical abnormalities can underestimate histological disease (7). Albuminuria improvement with an ARB does not establish a noninflammatory cause. KDIGO 2024 includes belimumab and CNI-based options alongside established regimens. It did not retroactively incorporate the subsequent 2025 obinutuzumab approval. ACR 2024 guidance was published in 2025; distinguish a guideline's name, publication date, and later evidence (7,8,10). ### The ACR Variability Problem: Why a Single Measurement Creates Uncertainty Spot ACR has substantial within-person variability. Studies in CKD and type 2 diabetes support repeat samples when judging a change, but their numerical variation limits are not a validated decision rule for this patient with suspected inflammatory disease (28,29). The rise from approximately 200 to 900 mg/g was 4.5-fold. Subsequent improvement could reflect treatment, biological variation, or both; it cannot distinguish hypertensive disease from glomerulonephritis. Repeat unexpected findings with a consistent collection method and reassess promptly when kidney function worsens. Do not postpone evaluation of rapidly progressive disease merely to complete a routine repeat-testing interval. ## 4. The Unifying Diagnosis: Renal-First, Serologically Quiet Class IV Lupus Nephritis ### Establishing the Diagnosis **Reported pathology:** Class IV-G (A), full-house immunofluorescence, activity index 9/24, chronicity index 8/12, and fibrocellular/fibrotic crescents. The treating team's reported diagnosis was lupus nephritis. **Diagnostic interpretation:** integrate the complete light-microscopy, immunofluorescence, and electron-microscopy findings with the clinical course and serological results. Infection-associated and other immune-complex diseases can show a full-house pattern and must be considered where appropriate (31). **Classification:** biopsy-proven Class III/IV contributes 10 EULAR/ACR points after a qualifying positive ANA entry criterion. The later positive SLE screen requires clarification of the laboratory method and result before asserting that this patient satisfies the 2019 criteria (13,14). ### Why This Presentation Pattern Matters Negative anti-dsDNA or normal complement must not provide false reassurance in the presence of active renal disease. Treatment assessment combines the histological activity and chronicity with function, infection risk, comorbidities, and patient priorities. Follow proteinuria, urine sediment, kidney function, and clinical status. Repeat serology remains useful in context, but normal baseline values limit its ability to serve as the sole response marker. A proposed tissue-localized immune mechanism is not a validated biomarker for selecting obinutuzumab over belimumab or another regimen. ## 5. Treatment Evidence: Critical Distinction Between Guideline Recommendations and Post-Hoc Trial Data A crucial element of evidence-based treatment selection is distinguishing between explicit guideline recommendations and clinical reasoning based on post-hoc trial analyses. Neither the 2024 ACR Guidelines nor the 2024 KDIGO Guidelines specifically address proteinuria thresholds as criteria for choosing between belimumab and obinutuzumab. ### 5.1 What the 2024 ACR Guidelines Actually Recommend For Class III/IV lupus nephritis, the 2024 ACR Guidelines recommend triple therapy consisting of glucocorticoids plus one of three regimens (8): - MPAA plus belimumab - MPAA plus CNI (voclosporin or tacrolimus) - Low-dose cyclophosphamide plus belimumab **For patients with proteinuria ≥3 g/g:** The guideline conditionally recommends a triple regimen containing MPAA plus CNI. The rationale is that CNI-containing regimens (voclosporin, tacrolimus) produce faster proteinuria reduction. **For patients with extra-renal manifestations:** The guideline conditionally recommends a triple regimen containing belimumab. ### 5.2 What the Guidelines Do NOT Address Neither the 2024 ACR nor KDIGO guidelines include obinutuzumab in their primary treatment algorithms. Both guidelines were developed and finalized **prior to the October 2025 FDA approval of obinutuzumab** for lupus nephritis. The guidelines therefore do not provide recommendations: - Comparing obinutuzumab to belimumab - Specifying proteinuria thresholds for obinutuzumab selection - Explicitly stating that belimumab should be avoided at UPCR ≥3 g/g ### 5.3 BLISS-LN Post-Hoc Analysis: Belimumab Efficacy by Proteinuria Threshold BLISS-LN randomized 448 patients. A subsequent exploratory analysis found clearer kidney-response improvement with belimumab in the baseline UPCR below 3 g/g subgroup; the response endpoint did not show observed improvement in the higher-proteinuria subgroup (9). These were descriptive subgroup findings, not a trial designed to prove that belimumab has no benefit above a cutoff. The analysis also reported fewer kidney-related events or death and fewer flares in the overall population. Heavy proteinuria can inform treatment discussion, but **UPCR ≥3 g/g is not a categorical exclusion of belimumab**. Consider guideline options, the totality of evidence, extrarenal disease, kidney function, and individual risks. ### 5.4 REGENCY Subgroup Analysis: Obinutuzumab Efficacy by Proteinuria and Class REGENCY randomized 271 adults with active lupus nephritis to obinutuzumab or placebo added to mycophenolate and glucocorticoids. Complete renal response at week 76 occurred in 46.4% versus 33.1%; the adjusted difference was 13.4 percentage points (95% CI 2.0–24.8). More serious adverse events, mainly infections and COVID-19-related events, occurred with obinutuzumab (10). This establishes efficacy against placebo plus standard therapy in the trial population. It does not establish superiority to belimumab, cyclophosphamide, or a CNI. Numerical subgroup patterns and indirect network comparisons cannot supply a head-to-head ranking for this dialysis-dependent patient (18). Obinutuzumab targets CD20-positive B cells. Peripheral depletion is not proof of complete kidney-tissue depletion or a demonstrated special benefit for serologically quiet disease. ### 5.5 CNI Caution with Impaired Kidney Function Severe kidney impairment and chronic scarring increase concern about CNI nephrotoxicity. Voclosporin trials excluded baseline eGFR ≤45 mL/min/1.73 m². Its label states that use at this level is not recommended unless benefit exceeds risk; this is not an absolute contraindication to all CNIs. KDIGO advises individualized risk-benefit assessment and close monitoring when considering CNIs with substantially impaired function (7). The reported creatinine of 2.5 mg/dL and estimated GFR around 25–30, followed by dialysis dependence, limit extrapolation from typical trial participants. For this case, specialist selection of an alternative is understandable. Explain the evidence gap and toxicity concerns rather than claiming that a single eGFR threshold universally prohibits tacrolimus or voclosporin. See the [voclosporin prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f489295-1156-52c7-5fd0-5c4c52f9b813). ### 5.6 Cyclophosphamide: Risk-Benefit Considerations Mycophenolate and cyclophosphamide are established options for proliferative lupus nephritis. Comparative trials and systematic reviews must be interpreted by regimen and population; they do not prove interchangeability in every severe presentation (19). Discuss infection, cytopenia, cumulative malignancy risk, gonadal toxicity, pregnancy prevention, and fertility preservation. Cyclophosphamide may remain appropriate in selected rapidly progressive or organ-threatening disease. Fibrous crescents indicate chronic injury, but mixed active/chronic pathology does not by itself settle drug choice. **Reported case plan:** mycophenolate plus obinutuzumab was selected, with cyclophosphamide considered as an alternative if necessary. This records the treating team's approach; it is not proof that cyclophosphamide should be reserved for salvage in similar patients. ## 6. Treatment Decision Framework for This Patient ### Patient-Specific Clinical Factors | Reported finding | Interpretation | |----|----| | UPCR 9.4 g/g | Severe proteinuria; informs risk and response monitoring, not an absolute biologic-selection rule. | | Creatinine 2.5 mg/dL before dialysis; estimated GFR approximately 25–30 | Severely impaired function limits trial applicability and increases drug-safety concerns. Creatinine-based eGFR is less reliable during rapid change. | | Activity index 9/24 | Active inflammatory lesions support prompt treatment evaluation. | | Chronicity index 8/12 | Substantial chronic injury reduces expected reversibility without yielding a precise prognosis. | | Negative anti-dsDNA; normal C3/C4 | Serology alone cannot track the full renal process or select a biologic. | | Class IV-G (A); fibrocellular and fibrotic crescents | Reported proliferative pathology with mixed active and chronic components. | ### 6.1 Weighing CNI Risk The low kidney function and high chronicity raise CNI toxicity concerns and limit evidence from voclosporin trials. These factors support considering other regimens. Any CNI use requires a specialist assessment of potential benefit, exposure, blood pressure, interactions, and kidney-function monitoring rather than application of a universal contraindication. ### 6.2 Interpreting Belimumab Evidence High baseline proteinuria may attenuate the kidney-response signal seen with belimumab in exploratory analyses (9). That uncertainty does not demonstrate absent benefit or exclude belimumab. Its possible effects on flares, longer-term kidney outcomes, and extrarenal lupus should be considered alongside competing treatments. ### 6.3 Weighing Cyclophosphamide The case reports a mycophenolate-based choice to limit cyclophosphamide exposure. Fertility goals and cumulative toxicity are relevant, but severity, prior response, adherence, and active lesions also matter. No preserved “salvage” option should substitute for selecting the most appropriate initial regimen for the individual. ### 6.4 Interpreting Obinutuzumab Evidence REGENCY supports obinutuzumab added to mycophenolate and glucocorticoids in active lupus nephritis (10). NOBILITY exploratory follow-up also suggested preservation of kidney function (20). These findings support discussion of this option, not a guaranteed recovery effect in advanced, dialysis-dependent disease. No cited head-to-head trial proves superiority over belimumab, and negative serology does not identify a validated preferential-response subgroup. ### 6.5 Reported Regimen and Safe Application **Reported treatment choice:** the case describes glucocorticoids with mycophenolate and obinutuzumab. Confirm the actual prescription, start dates, tolerability, and response from the clinical record; the narrative is not an order set. REGENCY used 1000 mg obinutuzumab on day 1 and weeks 2, 24, 26, and 52, with one study schedule also including week 50 (10). A trial schedule must be distinguished from the current approved regimen. Current adult lupus-nephritis labeling specifies initial, week 2, week 24, and week 26 infusions, then dosing every six months, beginning six months after dose 4. Use the [current prescribing information](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=df12ceb2-5b4b-4ab5-a317-2a36bf2a3cda) for the full regimen, premedication, and precautions. Glucocorticoid taper, mycophenolate exposure, pregnancy prevention, infection prophylaxis, and supportive care require individual review, particularly with dialysis. Blood pressure and volume management must account for dialysis tolerance rather than importing a nondialysis BP target without context. ## 6.7 Supportive Care: Hydroxychloroquine and PJP Prophylaxis ### Hydroxychloroquine: Dose and Retinal Surveillance Hydroxychloroquine is recommended for SLE, including lupus nephritis, unless contraindicated. Dose selection considers body weight, kidney function, interactions, and retinal risk (7). The AAO 2025 revision retains a recommended daily dose of no more than 5 mg/kg real body weight; this is not a guarantee of safety. It recommends baseline fundus examination, OCT, and fundus autofluorescence soon after starting treatment. Annual OCT/FAF screening is recommended during use; deferral during the first five years applies only when significant risk factors are absent (30). Renal disease increases retinal-toxicity risk. Arrange individualized dosing and early ophthalmology coordination in this dialysis-dependent patient. Do not assign a universal dialysis dose or imply that screening can routinely wait five years. ### PJP and Other Infection Prevention Intensive glucocorticoid and combination immunosuppression warrants active assessment for Pneumocystis jirovecii prophylaxis. Consider regimen, duration, lymphopenia, comorbidities, allergy, and adverse-effect risk (7). TMP-SMX is commonly used, but the prescription must match the indication, kidney function, and dialysis schedule. Monitor potassium, blood counts, and intolerance. This handout does not provide a universal dialysis dose; verify the plan with the treating team and renal pharmacist. Alternatives may include atovaquone, dapsone after G6PD assessment, or inhaled pentamidine, chosen for the clinical context. Also review hepatitis B screening before anti-CD20 therapy, vaccination timing, and instructions for urgent assessment of infection symptoms. Profound immunosuppression increases both treatment benefit considerations and infection harm. ### 6.8 Monitoring Strategy Track the clinical course, urine output, proteinuria, sediment, kidney-function trends, volume, and treatment toxicity. Dialysis timing affects creatinine interpretation, and eGFR formulas are unreliable during rapidly changing function. Normal anti-dsDNA and complement at baseline limit their usefulness as sole activity markers; they may still contribute to serial assessment. Drug-specific monitoring includes blood counts, infection surveillance, and other tests dictated by the regimen. Consider repeat biopsy when the response is inadequate or the distinction between active disease and chronic damage would change therapy. Monitoring intervals and any dialysis-reduction trial are individualized rather than fixed by this educational case. ## 7. Prognosis: Renal Recovery from Dialysis-Dependent Lupus Nephritis ### 7.1 The Significance of Continued Urine Output Continued urine production is clinically useful, but urine volume is not equivalent to effective solute clearance. Diuretics and fluid intake can alter volume without sufficient filtration to stop dialysis. General AKI studies associate oliguria with adverse outcomes (21,22). They do not validate lupus-specific recovery percentages for particular urine-volume bands. Avoid translating nonoliguric status into an individual probability of dialysis independence. ### 7.2 Prognostic Factors in Dialysis-Dependent Lupus Nephritis The reported active lesions may have a reversible component, whereas high chronicity and fibrous crescents indicate substantial established injury. Baseline function, recurrent flares, proteinuria, treatment response, intercurrent infection, and comorbid illness influence outcome. Age 35, ongoing urine output, activity index 9/24, chronicity index 8/12, UPCR 9.4 g/g, and dialysis dependence should be considered together. None supplies a validated arithmetic adjustment that can be added to or subtracted from a population recovery rate. Negative serology does not establish treatment resistance or a distinct prognosis. ### 7.3 Literature-Based Recovery Rates A retrospective cohort of 140 patients with lupus nephritis requiring kidney replacement therapy reported recovery in 75 patients (54%); cumulative recovery was 50.9% by six months and 54.2% by twelve months. Among those who recovered, 37 subsequently restarted kidney replacement therapy (32). This cohort shows that recovery can occur and may be followed by later kidney failure. It is not an individualized prediction for this patient, especially given differences in chronic damage and presentation. Infection-related hospitalization was frequent and reinforces the need to reassess treatment harms. General AKI, ANCA-associated disease, and anti-GBM cohorts describe different populations and cannot supply a lupus-specific recovery calculator (21–24). ### 7.4 Realistic Prognosis Assessment for This Patient **A reliable individual recovery percentage cannot be calculated from the supplied data.** Urine output and chronicity do not provide validated additive adjustments to a population recovery rate. Substantial chronic injury makes complete recovery less likely, while active inflammation may retain treatable components. The chronicity score alone does not establish the final CKD stage, percentage of sclerosed nephrons, exact dialysis duration, or inevitability of permanent failure. Discuss uncertainty openly: monitor for recovery while providing high-quality dialysis care and preparing for longer-term treatment if needed. Revisit expectations as objective clearance, laboratory trends, volume status, and clinical response evolve. ### 7.5 Monitoring for Signs of Renal Recovery - Measure urine-volume trends while accounting for diuretics and fluid intake. - Interpret interdialytic creatinine and urea trends with timing, nutrition, and muscle mass; collect timed urine clearance when useful and feasible. - Assess potassium, bicarbonate, symptoms, and volume balance rather than using urine volume alone. - Track proteinuria and sediment alongside treatment response and toxicity. - Any reduction or trial discontinuation of dialysis requires a nephrologist-directed monitoring and rescue plan. There is no single six-week, three-month, or six-month cutoff that proves irreversible failure in every patient. Recovery assessment and dialysis/transplant planning can proceed together. ### 7.6 Reassessing Immunosuppression During Dialysis Dialysis dependence alone does not show that active lupus treatment has failed or that all immunosuppression should stop. Conversely, dialysis dependence is not a reason to continue intensive therapy indefinitely. Repeatedly balance potentially reversible kidney activity and extrarenal disease against infection, cytopenia, drug toxicity, and the burden of chronic irreversible injury. Specialist decisions may include continuation, modification, or reduction of therapy as the evidence changes. Persistent severe infection or a biopsy dominated by irreversible scarring can change the balance substantially. Treatment decisions should follow the patient's evolving condition and preferences. ### 7.7 Limits of Kidney-Preservation Evidence A post hoc analysis of NOBILITY reported a slower annual eGFR decline with obinutuzumab than placebo, with a slope advantage of 4.1 mL/min/1.73 m²/year (95% CI 0.14–8.08), and favorable exploratory kidney-event outcomes (20). These results support further assessment of longer-term kidney protection in the studied population. They do not demonstrate that obinutuzumab will reverse dialysis dependence, overcome a chronicity index of 8/12, or outperform another active drug in this case. ## 8. Lessons for Future Practice ### 8.1 Confirm and Investigate Persistent Urine Abnormalities Confirm unexplained or potentially contaminated urine findings. Persistent hematuria with proteinuria, active sediment, hypertension, or impaired kidney function merits a structured renal evaluation. Referral and biopsy depend on the full context, not sex or reproductive age alone. ### 8.2 Interpret Serology in Context Interpret ANA, anti-dsDNA, and complement as parts of a diagnostic assessment. Negative results must not dismiss unexplained glomerular disease, but neither does a full-house pattern automatically diagnose lupus. Integrate pathology, clinical review, assay details, and alternative causes. ### 8.3 Act on a Worsening Trajectory Rapid loss of kidney function warrants urgent evaluation. Associations between delay and worse outcomes support prompt reassessment, but they cannot retrospectively prove how much injury an earlier intervention would have prevented in an individual. ### 8.4 Make a Contextual Biopsy Decision Use SLE biopsy guidance in its intended population and evaluate unexplained kidney disease even without an SLE diagnosis. The benefits of diagnostic tissue must be weighed against procedural risk; low proteinuria or normal serology alone cannot rule out important pathology. ### 8.5 Measure Albumin and Total Protein Appropriately ACR and UPCR are related but different measurements. Obtain the test relevant to the clinical decision, use consistent units, and repeat unexpected findings. A fixed ACR-to-UPCR conversion can mislead; improvement in one measure does not establish the cause of disease. ## 9. Summary and Key Teaching Points 1. Preserve the distinction between the treating team's diagnosis, the reported pathology, and research classification criteria. 2. Full-house staining is characteristic but not exclusive to lupus; the ANA entry criterion cannot be bypassed when applying the 2019 EULAR/ACR classification system. 3. Confirm persistent urine abnormalities and investigate a worsening kidney trajectory even when customary systemic clues are absent. 4. Do not substitute a fixed ACR-to-UPCR calculation for an actual total-protein measurement. 5. Apply guidelines and trials with attention to the studied population. Exploratory subgroups do not prove that belimumab has no benefit or that obinutuzumab is the best choice for this patient. 6. Severe impairment increases CNI risk; distinguish trial exclusion, label cautions, and absolute contraindications. 7. Use individualized drug monitoring, retinal screening, infection prevention, and dialysis-aware prescribing. 8. Urine output and chronicity inform prognosis but cannot generate a personalized recovery percentage. Reassess activity, recovery, and treatment harm over time. ## References 1. Arazi A, Rao DA, Berthier CC, et al. The immune cell landscape in kidneys of patients with lupus nephritis. Nat Immunol. 2019;20(7):902-914. [PubMed PMID 31209404](https://pubmed.ncbi.nlm.nih.gov/31209404/) 2. Carlucci PM, Li J, Fava A, et al. High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. Rheumatology (Oxford). 2022;61(11):4335-4343. [PubMed PMID 35212719](https://pubmed.ncbi.nlm.nih.gov/35212719/) 3. Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024;105(1S):S1-S69. [PubMed PMID 38182286](https://pubmed.ncbi.nlm.nih.gov/38182286/) 4. Sammaritano LR, Askanase A, Bermas BL, et al. 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis Rheumatol. 2025;77(9):1115-1135. [PubMed PMID 40331662](https://pubmed.ncbi.nlm.nih.gov/40331662/) 5. Rovin BH, Furie R, Teng YKO, et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 2022;101(2):403-413. [PubMed PMID 34560137](https://pubmed.ncbi.nlm.nih.gov/34560137/) 6. Furie RA, Rovin BH, Garg JP, et al. Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. N Engl J Med. 2025;392(15):1471-1483. [PubMed PMID 39927615](https://pubmed.ncbi.nlm.nih.gov/39927615/) 7. Faurschou M, Starklint H, Halberg P, et al. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol. 2006;33(8):1563-9. [PubMed PMID 16881113](https://pubmed.ncbi.nlm.nih.gov/16881113/) 8. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71(9):1400-1412. [PubMed PMID 31385462](https://pubmed.ncbi.nlm.nih.gov/31385462/) 9. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71(9):1400-1412. [PubMed PMID 31385462](https://pubmed.ncbi.nlm.nih.gov/31385462/) 10. Moroni G, Porata G, Raffiotta F, et al. Predictors of increase in chronicity index and of kidney function impairment at repeat biopsy in lupus nephritis. Lupus Sci Med. 2022;9(1). [PubMed PMID 35973744](https://pubmed.ncbi.nlm.nih.gov/35973744/) 11. Perge B, Papp G, Bói B, et al. Prognostic Factors of the Progression of Chronic Kidney Disease and the Development of End-Stage Renal Disease in Patients with Lupus Nephritis: A Retrospective Cohort Study. J Clin Med. 2025;14(3). [PubMed PMID 39941336](https://pubmed.ncbi.nlm.nih.gov/39941336/) 12. Norouzi S, Contreras GN. KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. Am J Kidney Dis. 2026;88(2):179-195. [PubMed PMID 42481080](https://pubmed.ncbi.nlm.nih.gov/42481080/) 13. Liu X, Chen X, Yang C, et al. Biologicals for the treatment of lupus nephritis: a Bayesian network meta-regression analysis. Front Immunol. 2024;15:1445814. [PubMed PMID 39281677](https://pubmed.ncbi.nlm.nih.gov/39281677/) 14. Tunnicliffe DJ, Palmer SC, Henderson L, et al. Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst Rev. 2018;6(6):CD002922. [PubMed PMID 29957821](https://pubmed.ncbi.nlm.nih.gov/29957821/) 15. Rovin BH, Furie RA, Ross Terres JA, et al. Kidney Outcomes and Preservation of Kidney Function With Obinutuzumab in Patients With Lupus Nephritis: A Post Hoc Analysis of the NOBILITY Trial. Arthritis Rheumatol. 2024;76(2):247-254. [PubMed PMID 37947366](https://pubmed.ncbi.nlm.nih.gov/37947366/) 16. Kellum JA, Sileanu FE, Murugan R, et al. Classifying AKI by Urine Output versus Serum Creatinine Level. J Am Soc Nephrol. 2015;26(9):2231-8. [PubMed PMID 25568178](https://pubmed.ncbi.nlm.nih.gov/25568178/) 17. Macedo E, Malhotra R, Bouchard J, et al. Oliguria is an early predictor of higher mortality in critically ill patients. Kidney Int. 2011;80(7):760-7. [PubMed PMID 21716258](https://pubmed.ncbi.nlm.nih.gov/21716258/) 18. Chen M, Kallenberg CG, Zhao MH. ANCA-negative pauci-immune crescentic glomerulonephritis. Nat Rev Nephrol. 2009;5(6):313-8. [PubMed PMID 19399019](https://pubmed.ncbi.nlm.nih.gov/19399019/) 19. Levy JB, Turner AN, Rees AJ, et al. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001;134(11):1033-42. [PubMed PMID 11388816](https://pubmed.ncbi.nlm.nih.gov/11388816/) 20. Lopez E, Hanna RM, Wilson J. Decreased sensitivity of anti-dsDNA antibody assay observed in a cohort of Hispanic patients with biopsy-proven lupus nephritis. Saudi J Kidney Dis Transpl. 2016;27(6):1270-1273. [PubMed PMID 27900979](https://pubmed.ncbi.nlm.nih.gov/27900979/) 21. Jain D, Aggarwal HK, Kaverappa V, et al. Anti-dsDNA negative and anti-Ro positive lupus nephritis: a report of a rare case. Reumatismo. 2014;65(6):302-6. [PubMed PMID 24705035](https://pubmed.ncbi.nlm.nih.gov/24705035/) 22. Naresh CN, Hayen A, Weening A, et al. Day-to-day variability in spot urine albumin-creatinine ratio. Am J Kidney Dis. 2013;62(6):1095-101. [PubMed PMID 23958401](https://pubmed.ncbi.nlm.nih.gov/23958401/) 23. Rasaratnam N, Salim A, Blackberry I, et al. Urine Albumin-Creatinine Ratio Variability in People With Type 2 Diabetes: Clinical and Research Implications. Am J Kidney Dis. 2024;84(1):8-17.e1. [PubMed PMID 38551531](https://pubmed.ncbi.nlm.nih.gov/38551531/) 24. Marmor MF, Ahn SJ, Ehlers JP, et al. Special AAO Report: Recommendations on Screening for Hydroxychloroquine Retinopathy (2025 Revision). Ophthalmology. 2026;133(4):439-450. [PubMed PMID 41232611](https://pubmed.ncbi.nlm.nih.gov/41232611/) 25. Uzzo M, Kronbichler A, Alberici F, et al. Nonlupus Full House Nephropathy: A Systematic Review. Clin J Am Soc Nephrol. 2024;19(6):743-754. [PubMed PMID 38527995](https://pubmed.ncbi.nlm.nih.gov/38527995/) 26. Márquez-Macedo SE, Perez-Arias AA, Pena-Vizcarra ÓR, et al. Predictors of treatment outcomes in lupus nephritis with severe acute kidney injury and requirement of dialytic support. Clin Rheumatol. 2023;42(8):2115-2123. [PubMed PMID 37188962](https://pubmed.ncbi.nlm.nih.gov/37188962/) ------------------------------------------------------------------------ *Case prepared for educational purposes. Patient details have been modified to protect confidentiality. All clinical decisions should be made in consultation with appropriate specialists.* *This educational review was prepared by the Medical Associates Department of Nephrology in collaboration with the University of Illinois College of Medicine at Peoria, the University of Dubuque Physician Assistant Program, and the UDPA Butler School of Medicine. It is intended for use in clinical education and does not constitute individualized medical advice.* *© 2026 Medical Associates Department of Nephrology — Lupus Nephritis Education Series* ## Related Notes - ← Back to Glomerular Diseases Hub - Treatment Evidence Review - Patient Education Handout ## Educational Resources - Student Guide: Lupus Nephritis Treatment Evidence Review V2 — PA/medical student educational guide --- [Website version](https://urinenephrology.org/case-reports/lupus-nephritis-renal-first.html) · Markdown synchronized October 3, 2026.